NantHealth Announces Commercial Availability of GPS Cancer™ and Launch of GPS Cancer Browser on a Secure Mobile Platform at the 2016 American Society of Clinical Oncology Annual Meeting

NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, announced today the commercial availability of Genomic Proteomic Spectrometry Cancer, or GPS Cancer, a unique, comprehensive molecular test and decision support solution that measures the proteins present in the patient's tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor & normal samples. Read the full press release HERE.